New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
08:22 EDTDRTXDurata Therapeutics says EMA accepts marketing application for dalbavancin
Durata Therapeutics announced that the European Medicines Agency, EMA, has accepted for review a Marketing Authorization Application for dalbavancin. Durata is seeking approval for the marketing and sale of dalbavancin for the treatment of patients with complicated skin and soft tissue infections caused by susceptible Gram-positive microorganisms, including Staphylococcus aureus and Streptococcus pyogenes, as well as certain other streptococcal species. The start of the review procedure begins December 26. The company anticipates a decision in 1H15.
News For DRTX From The Last 14 Days
Check below for free stories on DRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
08:22 EDTDRTXDurata Therapeutics initiated with a Buy at Summer Street
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use